The MSLN gene encodes a precursor protein that undergoes proteolytic processing to generate two protein products: megakaryocyte potentiating factor and mesothelin. The megakaryocyte potentiating factor acts as a cytokine that stimulates bone marrow megakaryocyte colony formation. Mesothelin is primarily located on the surface of normal mesothelial cells and is expressed only in mesothelial cells in normal tissues. However, it is highly expressed in tumors such as mesothelioma, ovarian cancer, pancreatic cancer, and cholangiocarcinoma. MSLN is overexpressed in 80% to 90% of pancreatic ductal adenocarcinomas, making this target an attractive candidate for the treatment of pancreatic ductal adenocarcinoma patients. Mesothelin is a promising tumor-specific therapeutic candidate target. FITC-labeled MSLN/Mesothelin Fc chimera protein can be used to quantitatively detect the expression level and binding activity of MSLN protein, providing a technical tool for targeted therapy research of solid tumors.
MSLN promotes tumor cell survival and proliferation through the ERK and PI3K/Akt pathways and enhances invasiveness and metastatic processes through the activity of MMP-7. MSLN binds to MUC16 on the surface of pancreatic cancer cells, activating the p38 MAPK-dependent pathway, which upregulates the synthesis of MMP-7, leading to increased invasion and migration potential. In pancreatic cancer cells that do not express MUC16, MSLN can upregulate MMP-7 expression by activating the ERK-dependent pathway. The fundamental mechanisms linking MSLN with EMT and angiogenesis in pancreatic ductal adenocarcinoma remain to be elucidated. FITC-labeled MSLN/Mesothelin Fc chimera protein can be used to study the interaction between MSLN and MUC16, providing quantitative analysis methods for mechanistic research.
The binding of MSLN and MUC16 plays a significant role in tumor metastasis. MSLN binds to MUC16 on the surface of pancreatic cancer cells, activating the p38 MAPK-dependent pathway, which upregulates the synthesis of MMP-7, leading to increased invasion and migration potential. In pancreatic cancer cells that do not express MUC16, MSLN can upregulate MMP-7 expression by activating the ERK-dependent pathway. Through interaction with MUC16-expressing cells, MSLN can also promote metastasis. This interaction provides a molecular basis for the spread and colonization of tumor cells in the peritoneal cavity. Targeting this interaction may be an effective strategy to inhibit tumor metastasis. FITC-labeled MSLN/Mesothelin Fc chimera protein can be used to evaluate the binding properties of MSLN and MUC16, providing a screening tool for developing therapeutic drugs that block this interaction.
Among current drugs targeting MSLN for solid tumor treatment, monoclonal antibodies are an important research direction. These antibodies specifically recognize MSLN protein and can mediate antibody-dependent cellular cytotoxicity (ADCC) to exert anti-tumor activity. Monoclonal antibody drugs can be used alone or in combination with other therapeutic strategies. Due to the high expression of MSLN in tumor tissues and limited expression in normal tissues, it is an ideal therapeutic target. The advantages of monoclonal antibody drugs include high specificity and relatively low toxicity and side effects. FITC-labeled MSLN/Mesothelin Fc chimera protein can be used to assess the binding capability of monoclonal antibodies to MSLN antigen and validate their functional activity.
Monoclonal antibody drugs carrying protein toxins or low-molecular-weight cytotoxic agents are an important strategy for targeting MSLN. These drugs use antibodies to specifically recognize MSLN and deliver toxins or cytotoxic agents precisely to MSLN-positive tumor cells. Upon binding to MSLN, the toxins or drugs are internalized and exert their killing effects. This strategy enhances efficacy and reduces systemic toxicity. Antibody-drug conjugates have shown certain anti-tumor activity in patients with MSLN-positive solid tumors. FITC-labeled MSLN/Mesothelin Fc chimera protein can be used to evaluate the binding capability of antibody-drug conjugates to MSLN antigen and validate their targeting specificity.
CAR-T cell drugs targeting MSLN are an important direction in immunotherapy. CAR-T cells express chimeric antigen receptors that specifically recognize MSLN, enabling precise targeting and elimination of MSLN-expressing tumor cells. Compared to traditional treatments, CAR-T cell therapy offers advantages such as high specificity, potent killing activity, and the ability to generate immune memory. Additionally, vaccines that induce T-cell immune responses against MSLN are under investigation. These vaccines activate the patient's immune system to produce T-cell responses that specifically recognize MSLN, inhibiting tumor growth. FITC-labeled MSLN/Mesothelin Fc chimera protein can be used to assess the binding capability of CAR-T cells to MSLN antigen and validate their functional activity.
As a specific marker molecule for solid tumors, MSLN demonstrates broad application prospects in targeted therapy and immunotherapy. FITC-labeled MSLN/Mesothelin Fc chimera protein provides a sensitive and efficient detection tool for studying the expression, distribution, and interactions of MSLN protein. It can be applied in various stages, including antibody screening, CAR-T cell functional evaluation, and immune monitoring.
Nanjing UA-Bio Technology Co., Ltd. has independently developed the "FITC-Labeled MSLN/Mesothelin Fc Chimera Protein, Human" (Catalog Number: UA011264), a high-performance green fluorescent-labeled probe specifically designed for mesothelin (MSLN) targeting research and solid tumor immunotherapy evaluation. Mesothelin (MSLN) is a glycoprotein highly expressed on the surface of various solid tumor cells, including mesothelioma, pancreatic cancer, ovarian cancer, and lung cancer, making it an important target for tumor immunotherapy.
| Core Advantages of the Product | Detailed Parameters / Functional Description |
|---|---|
| High Purity and Complete Biological Activity | The product is produced using an internationally advanced eukaryotic expression system and a highly standardized purification process, with multi-dimensional quality control verification to ensure >95% purity and correct native conformation (retaining complete glycosylation modifications). The Fc chimera form helps maintain protein stability and proper folding. The FITC labeling process is optimized to ensure high labeling efficiency while maintaining high-affinity binding to antibodies, accurately simulating the antigenic properties of MSLN on the surface of solid tumor cells such as mesothelioma and pancreatic cancer.-- |
| High-Brightness FITC Labeling | The optimized FITC fluorescent labeling process ensures that each MSLN-Fc chimera protein molecule has a stable number of fluorescent dye labels, emitting bright green fluorescence signals under 488 nm excitation. This makes it suitable for flow cytometry (FACS) and fluorescence microscopy detection, providing reliable support for the evaluation and precise quantification of MSLN-targeting molecules.-- |
| Excellent Batch-to-Batch Consistency and Stability | Strict management is implemented throughout the entire process, from protein expression and labeling to purification and quality control, combined with a comprehensive release testing system. This ensures that each batch of products has stable binding activity, consistent fluorescence intensity, and excellent long-term stability, providing a solid and reliable quality guarantee for your long-term and continuous MSLN-targeting research.-- |
| Ideal Tool for Multi-Scenario Applications | This protein performs excellently in various application systems, including CAR-T cell positivity rate detection by flow cytometry, anti-MSLN antibody/antagonist screening, competitive binding assays, detection and analysis of solid tumor markers (such as mesothelioma, pancreatic cancer, and ovarian cancer), and flow cytometry. It is widely applicable to MSLN-targeted CAR-T cell therapy product development, solid tumor diagnostic tool research, and drug activity evaluation.-- |
| Complete Solutions and Professional Support | We provide fully validated standard experimental protocols, typical flow cytometry data, and detailed result interpretation guidelines to help you quickly establish stable and reproducible MSLN-targeting molecule detection processes. The professional technical team at Nanjing UA-Bio can provide comprehensive technical consultation and support for your research design, experimental optimization, and data analysis.-- |
Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding "FITC-Labeled MSLN/Mesothelin Fc Chimera Protein, Human" (Catalog Number: UA011264), please feel free to contact us.
